Baseline keyword and SERP landscape captured for semaglutides.org

On September 14, 2026, semaglutides.org completed a research pass focused on tirzepatide, the active ingredient in Mounjaro and Zepbound. The project pulled 13,213 U.S. search queries from Google and DuckDuckGo autocomplete tools across 86 starting search terms, then grouped them into 38 topic clusters ^[1][2]. The team also checked 75 competitor web pages to see which were still active, and reviewed discussion on three Reddit communities: r/Zepbound, r/Mounjaro and r/compoundedtirzepatide ^[3][4].

This pass builds on earlier work. Before this update, the site had tracked 67 Mounjaro-related queries and 88 Zepbound-related queries. The new pass raises total tracked tirzepatide queries to 1,213, according to the project summary. As a result, the site is adding dedicated root-level pages for Mounjaro, Zepbound and tirzepatide, giving these topics their own place in the site's structure rather than folding them into general semaglutide content ^[1][2].

It's worth noting that the underlying data sources used for this reporting — the Google and DuckDuckGo autocomplete tools and the Reddit pages themselves — could not be independently reviewed here. The autocomplete tool requests returned an error rather than usable text ^[1][2], and the Reddit community pages were blocked from direct access ^[3][4]. That means the specific search phrases, topic groupings, and Reddit comments behind these numbers come from the project's own summary rather than from source text that could be quoted or checked line by line.

Why it matters for patients

This update is about how information is organized on this site, not about a new drug, a new study, or a new safety finding. Still, it has practical implications for people researching tirzepatide medications. A larger set of tracked search queries, built from what real users type into search engines, suggests the site is trying to match its content to the actual questions people have about Mounjaro and Zepbound — for example, cost, side effects, or how compounded versions differ from brand-name products, since r/compoundedtirzepatide was specifically included in the review ^[3][4].

The inclusion of compounded tirzepatide discussion is notable given that compounded versions of GLP-1 drugs have been a source of confusion and concern for patients, since they are not the same FDA-approved products as Mounjaro or Zepbound. Readers should know that this update itself does not report new facts about the safety or effectiveness of compounded tirzepatide — it only reflects that the topic is part of what people are searching for and discussing online ^[3][4].

New hub pages for Mounjaro, Zepbound and tirzepatide may make it easier for readers to find information specific to those brands rather than searching through general semaglutide content, since semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are different drugs with different mechanisms, even though both are GLP-1 class medications.

What happens next

The summary does not specify a date for when the new Mounjaro, Zepbound and tirzepatide hub pages will go live, nor does it describe what content will appear on them. It also does not say whether additional research passes are planned for semaglutide-specific queries or for orforglipron (Foundayo), which is not mentioned in this update. Readers looking for clinical or safety information on these drugs should look for future site updates or consult other verified sources, since this development concerns research and site structure rather than new medical findings.